Skip to main content

Day: May 19, 2023

Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) is meeting today to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). The Advisory Committee meeting is scheduled for 9:00 a.m. – 5:00 p.m. ET. The briefing materials can be found on the FDA website (click here). As previously reported, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 22, 2023. The timeline...

Continue reading

First Ever NFT as a Movie, Zero Contact Starring Anthony Hopkins Goes Global at Cannes Film Festival

Filmed in 17 Different Countries, Including the First Scripted Feature Ever to Film in Antarctica, Hits Cannes Film Festival to Distribute the Film Internationally through Opus One Pictures Fairfield, CA., May 19, 2023 (GLOBE NEWSWIRE) — MetaWorks Platforms, Inc. (“MetaWorks” or the “Company”), (CSE: MWRK and OTCQB: MWRK), an award-winning Web3 company that owns and operates blockchain platforms in the entertainment & technology space, today announced that, on the heels of its agreement to sell the International rights of the film ZERO CONTACT, the world’s first ever full length feature film to be launched as an NFT, the movie is now being offered for distribution in all 17 of the countries the film was produced in through its deal with Opus One Pictures at the Cannes Film Festival. ZERO CONTACT made film history by becoming...

Continue reading

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

Company prioritizes education with a variety of in-person and virtual training programs MALVERN, Pa., May 19, 2023 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced it will be hosting its next cadaver lab on May 19 in Tampa, Florida. The upcoming program, “Advanced Hernia Repair with OviTex® Reinforced Tissue Matrix,” will provide surgeons the opportunity to learn innovative open and robotic-assisted hernia repair techniques. TELA Bio has partnered with key opinion leaders in general and plastic and reconstructive surgery to develop a series of interactive medical education programs focused on the safe and effective...

Continue reading

Virtu Financial Congratulates Helen Ren, Recipient of the Rising Star Award at Women in Finance Asia

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ: VIRT) a leading provider of financial services and products that leverage cutting-edge technology to deliver innovative, transparent trading solutions to our clients and liquidity to the global markets, is pleased to congratulate and recognize Helen Ren for being awarded the Rising Star award at Markets Media’s Women in Finance Asia Awards. The prestigious award recognizes women who have made a significant contribution to the financial industry with their entrepreneurial spirit and leadership. “I am thrilled to see Helen recognized with the Rising Star award. It is a testament to her hard work, collegiality, and exceptional performance,” said Steve Cavoli, Global Head of Execution Services at Virtu Financial. “She’s an asset to our team, and I am so proud...

Continue reading

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of liquid and solid tumors Company plans to share initial safety and proof-of-mechanism clinical data in second half of 2023 WATERTOWN, Mass., May 19, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, has recently dosed the first patient in the Phase 1 multicenter, open-label, dose-escalation clinical trial evaluating its investigational MDM2 degrader KT-253. The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and clinical activity of ascending...

Continue reading

Bilibili Inc. to Report First Quarter 2023 Financial Results on Thursday, June 1, 2023

Earnings Call Scheduled for 8:00 a.m. ET on June 1, 2023 SHANGHAI, China, May 19, 2023 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it will report its first quarter 2023 unaudited financial results on Thursday, June 1, 2023, before the open of U.S. markets. The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on June 1, 2023 (8:00 PM Beijing/Hong Kong Time on June 1, 2023). Details for the conference call are as follows:Event Title: Bilibili Inc. First Quarter 2023 Earnings Conference CallRegistration Link: https://register.vevent.com/register/BI97fa686598904dc99838229131aefe79   All participants must use the link provided above to...

Continue reading

Medallion Financial Corp. to Participate in Upcoming Investor Conference

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — Medallion Financial Corp. (NASDAQ: MFIN, “Medallion” or the “Company”), a specialty finance company that originates and services loans in various consumer and commercial industries, along with offering loan origination services to fintech strategic partners, announced today it will participate in the upcoming 23rd Annual B. Riley Securities Institutional Investor Conference. 23rd Annual B. Riley Securities Institutional Investor ConferenceThe Conference will take place at the Beverly Hilton Hotel May 24-25, 2023 MFIN management will participate in a fireside chat on Wednesday, May 24 from 8:15 a.m. until 8:55 a.m. PT MFIN management will also be available for one-on-one meetings throughout the conference. For more information about the conference or to schedule a one-on-one meeting with...

Continue reading

Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference

MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use of YUTREPIA™ (treprostinil) inhalation powder at the 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, D.C. Thematic Poster Session: B64 – The Multiple Components of Pulmonary Rehabilitation Date and time: Monday, May 22, 2023, 11:30 a.m. – 1:15 p.m. ETLocation: Area J, Hall C (Lower Level), Walter E. Washington Convention CenterPresenting Author: Charles Burger, M.D., from the Mayo Clinic, Jacksonville, FloridaAbstract: Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study with Inhaled Treprostinil (Yutrepia™) Following the presentation, the...

Continue reading

Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

 Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® (golimumab) initiated, marking the fifth internally developed portfolio candidate to be dosed in a patient study Satisfactory outcome of facility reinspection remains the key requirement for U.S. approval of Biologics License Applications (BLAs) for AVT02, a proposed high-concentration, interchangeable biosimilar to Humira® (adalimumab) Management will conduct a business update conference call and live webcast on Friday, May 19, 2023, at 8:00 am ET (13:00 pm GMT)Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Continue reading

Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update

Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® (golimumab) initiated, marking the fifth internally developed portfolio candidate to be dosed in a patient studySatisfactory outcome of facility reinspection remains the key requirement for U.S. approval of Biologics License Applications (BLAs) for AVT02, a proposed high-concentration, interchangeable biosimilar to Humira® (adalimumab)Management will conduct a business update conference call and live webcast on Friday, May 19, 2023, at 8:00 am ET (12:00 pm GMT)REYKJAVIK, Iceland, May 19, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.